[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer].
The pharmacokinetic of 5-Fluorouracil and its permeation into malignant pleural effusion was investigated in 9 patients with breast carcinoma who received 600 mg/m2 5-Fluorouracil i.v. within the CMF protocol. Despite the short plasma halflife of 5-Fluorouracil (16,8 min) distinct concentrations with peak levels up to 115 nmol/ml after 30 min were observed in the effusions. In consequence of the rapid elimination of 5-Fluorouracil from the plasma and the comparatively slow retrograde diffusion (t 1/2 55 min) from the pleural space, the drug levels persisted longer in the effusions, than in the blood. Thus the area under the curve of the pleural level (AUC) reached 50% (27-85%) of the corresponding plasma AUC (10,9 +/- 2,3 mumol x min x ml-1). From a pharmacokinetic point of view, no additional local instillations of 5-Fluorouracil are necessary during a systemic therapy of breast cancer with pleural effusions.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001682:Biological Availability; D001943:Breast Neoplasms / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010996:Pleural Effusion / Q000378:metabolism*; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary*
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Die Pharmakokinetik von 5-Fluorouracil und seine Permeation in Pleuraergüsse bei der Therapie des metastasierenden Mamma-Karzinoms.